256 related articles for article (PubMed ID: 33724679)
1. CRISPR screens identify tumor-promoting genes conferring melanoma cell plasticity and resistance.
Gautron A; Bachelot L; Aubry M; Leclerc D; Quéméner AM; Corre S; Rambow F; Paris A; Tardif N; Leclair HM; Marin-Bejar O; Coulouarn C; Marine JC; Galibert MD; Gilot D
EMBO Mol Med; 2021 May; 13(5):e13466. PubMed ID: 33724679
[TBL] [Abstract][Full Text] [Related]
2. Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma.
Corre S; Tardif N; Mouchet N; Leclair HM; Boussemart L; Gautron A; Bachelot L; Perrot A; Soshilov A; Rogiers A; Rambow F; Dumontet E; Tarte K; Bessede A; Guillemin GJ; Marine JC; Denison MS; Gilot D; Galibert MD
Nat Commun; 2018 Nov; 9(1):4775. PubMed ID: 30429474
[TBL] [Abstract][Full Text] [Related]
3. WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.
Anastas JN; Kulikauskas RM; Tamir T; Rizos H; Long GV; von Euw EM; Yang PT; Chen HW; Haydu L; Toroni RA; Lucero OM; Chien AJ; Moon RT
J Clin Invest; 2014 Jul; 124(7):2877-90. PubMed ID: 24865425
[TBL] [Abstract][Full Text] [Related]
4. AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma.
Zuo Q; Liu J; Huang L; Qin Y; Hawley T; Seo C; Merlino G; Yu Y
Oncogene; 2018 Jun; 37(24):3275-3289. PubMed ID: 29551771
[TBL] [Abstract][Full Text] [Related]
5. CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-resistant Melanoma.
Li Z; Wang B; Gu S; Jiang P; Sahu A; Chen CH; Han T; Shi S; Wang X; Traugh N; Liu H; Liu Y; Wu Q; Brown M; Xiao T; Boland GM; Shirley Liu X
Genomics Proteomics Bioinformatics; 2020 Feb; 18(1):26-40. PubMed ID: 32413516
[TBL] [Abstract][Full Text] [Related]
6. Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma.
Marusak C; Thakur V; Li Y; Freitas JT; Zmina PM; Thakur VS; Chang M; Gao M; Tan J; Xiao M; Lu Y; Mills GB; Flaherty K; Frederick DT; Miao B; Sullivan RJ; Moll T; Boland GM; Herlyn M; Zhang G; Bedogni B
Clin Cancer Res; 2020 Nov; 26(22):6039-6050. PubMed ID: 32820016
[TBL] [Abstract][Full Text] [Related]
7. p38 MAPK-dependent phosphorylation of transcription factor SOX2 promotes an adaptive response to BRAF inhibitors in melanoma cells.
Pietrobono S; De Paolo R; Mangiameli D; Marranci A; Battisti I; Franchin C; Arrigoni G; Melisi D; Poliseno L; Stecca B
J Biol Chem; 2022 Sep; 298(9):102353. PubMed ID: 35944584
[TBL] [Abstract][Full Text] [Related]
8. Role of Flavonoids in the Prevention of AhR-Dependent Resistance During Treatment with BRAF Inhibitors.
Leclair HM; Tardif N; Paris A; Galibert MD; Corre S
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708687
[TBL] [Abstract][Full Text] [Related]
9. Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis.
Bonfill-Teixidor E; Iurlaro R; Handl C; Wichmann J; Arias A; Cuartas I; Emmenegger J; Romagnani A; Mangano L; Lorber T; Berrera M; Godfried Sie C; Köchl F; Eckmann J; Feddersen R; Kornacker M; Schnetzler G; Cicuendez M; Cordero E; Topczewski TE; Ferres-Pijoan A; González J; Martínez-Ricarte F; Muñoz-Couselo E; Tabernero J; Bischoff JR; Pettazzoni P; Seoane J
Cancer Res; 2022 Jul; 82(14):2552-2564. PubMed ID: 35584009
[TBL] [Abstract][Full Text] [Related]
10. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432
[TBL] [Abstract][Full Text] [Related]
11. ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.
Ojha R; Leli NM; Onorati A; Piao S; Verginadis II; Tameire F; Rebecca VW; Chude CI; Murugan S; Fennelly C; Noguera-Ortega E; Chu CT; Liu S; Xu X; Krepler C; Xiao M; Xu W; Wei Z; Frederick DT; Boland G; Mitchell TC; Karakousis GC; Schuchter LM; Flaherty KT; Zhang G; Herlyn M; Koumenis C; Amaravadi RK
Cancer Discov; 2019 Mar; 9(3):396-415. PubMed ID: 30563872
[TBL] [Abstract][Full Text] [Related]
12. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor.
Caporali S; Alvino E; Lacal PM; Levati L; Giurato G; Memoli D; Caprini E; Antonini Cappellini GC; D'Atri S
Int J Oncol; 2016 Sep; 49(3):1164-74. PubMed ID: 27572607
[TBL] [Abstract][Full Text] [Related]
13. The AhR-SRC axis as a therapeutic vulnerability in BRAFi-resistant melanoma.
Paris A; Tardif N; Baietti FM; Berra C; Leclair HM; Leucci E; Galibert MD; Corre S
EMBO Mol Med; 2022 Dec; 14(12):e15677. PubMed ID: 36305167
[TBL] [Abstract][Full Text] [Related]
14. miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment.
Liu S; Tetzlaff MT; Wang T; Yang R; Xie L; Zhang G; Krepler C; Xiao M; Beqiri M; Xu W; Karakousis G; Schuchter L; Amaravadi RK; Xu W; Wei Z; Herlyn M; Yao Y; Zhang L; Wang Y; Zhang L; Xu X
Pigment Cell Melanoma Res; 2015 Jul; 28(4):431-41. PubMed ID: 25903073
[TBL] [Abstract][Full Text] [Related]
15. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS
Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323
[TBL] [Abstract][Full Text] [Related]
16. Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance.
Sandri S; Watanabe LRM; Oliveira EA; Faião-Flores F; Migliorini S; Tiago M; Felipe-Silva A; Vazquez VL; da Costa Souza P; Consolaro MEL; Campa A; Maria-Engler SS
Pharmacol Res; 2020 Sep; 159():104998. PubMed ID: 32535222
[TBL] [Abstract][Full Text] [Related]
17. Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells.
Mologni L; Costanza M; Sharma GG; Viltadi M; Massimino L; Citterio S; Purgante S; Raman H; Pirola A; Zucchetti M; Piazza R; Gambacorti-Passerini C
Neoplasia; 2018 May; 20(5):467-477. PubMed ID: 29605720
[TBL] [Abstract][Full Text] [Related]
18. PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.
Lu H; Liu S; Zhang G; Bin Wu ; Zhu Y; Frederick DT; Hu Y; Zhong W; Randell S; Sadek N; Zhang W; Chen G; Cheng C; Zeng J; Wu LW; Zhang J; Liu X; Xu W; Krepler C; Sproesser K; Xiao M; Miao B; Liu J; Song CD; Liu JY; Karakousis GC; Schuchter LM; Lu Y; Mills G; Cong Y; Chernoff J; Guo J; Boland GM; Sullivan RJ; Wei Z; Field J; Amaravadi RK; Flaherty KT; Herlyn M; Xu X; Guo W
Nature; 2017 Oct; 550(7674):133-136. PubMed ID: 28953887
[TBL] [Abstract][Full Text] [Related]
19. Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.
Shen CH; Kim SH; Trousil S; Frederick DT; Piris A; Yuan P; Cai L; Gu L; Li M; Lee JH; Mitra D; Fisher DE; Sullivan RJ; Flaherty KT; Zheng B
Nat Med; 2016 Sep; 22(9):1056-61. PubMed ID: 27500726
[TBL] [Abstract][Full Text] [Related]
20. Sestrin2 contributes to BRAF inhibitor resistance via reducing redox vulnerability of melanoma cells.
Guo S; Yue Q; Wang S; Wang H; Ye Z; Zhang W; Shi Q; Gao T; Li C; Zhu G
J Dermatol Sci; 2023 Feb; 109(2):52-60. PubMed ID: 36858850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
